This technology describes methods and strategies for targeting oncogenic lipids for the treatment of cancer.
Many existing cancer treatments target oncogenic proteins resulting from metabolic dysregulation in cancer cells. However, these approaches commonly result in the development of treatment-resistant cells. Therapeutics that directly target metabolic pathways could potentially could avoid such risk of treatment resistance.
This technology describes approaches for targeting dysregulated metabolism found in cancer cells. By directly targeting the pathways that produce oncogenic lipids, this technology offers a therapeutic strategy that provides a higher therapeutic index, reduces the probability of treatment resistance, and has greater widespread applicability.
IR CU20221
Licensing Contact: Beth Kauderer